However, more comprehensive data are needed (linking ambulance
to trauma registry and long-term outcomes) to understand which Selleckchem Alvocidib patients benefit from a HEMS intervention and why. From the health system perspective, such data would allow for possible improvements in the cost-effectiveness of a HEMS intervention . Additionally, from the perspective of the receiving hospital, improved HEMS triage would possibly Inhibitors,research,lifescience,medical allow more efficient resource allocation to patients who require more of the services offered at a major trauma centre. During the study period, a HEMS pre-hospital and inter-hospital patient cost, on average, ~$25,000 and ~$42,000 respectively Inhibitors,research,lifescience,medical to treat, although considerable variation existed between patients, which has also been demonstrated previously . Our results show HEMS patients are potentially underfunded in the order of ~$2,500 – ~$2,900 per patient transported pre-hospital and inter-hospital respectively. Overall, the potential funding discrepancy was over $1.7 m for the entire year. These results support the need for further research to refine funding models to account Inhibitors,research,lifescience,medical for the complexity of trauma patients. In terms of the cost of over-triage to the major trauma centre, we found treating patients transported by HEMS with minor to moderate
injuries (according to the NSW definition; ISS<12) led to a shortfall between the cost of treatment and Inhibitors,research,lifescience,medical potential reimbursement of ~$542,000,
split evenly between pre-hospital and inter-hospital transports. Previous research has shown more inaccuracy in the episode funding model in less severely injured patients  and our results support these findings. Although a proportion of pre-hospital over-triaged patients would have received care at the same centre if transported by other transport modes, HEMS pre-hospital responses in NSW often bypass the closest designated trauma Inhibitors,research,lifescience,medical hospital . Therefore, the cost implications of HEMS over-triage to a major trauma centre is a significant consideration. Another implication of our results is the difference in patient acuity, cost and reimbursement between HEMS patients transported directly from the scene and inter-hospital. Our findings showed science patients transported inter-hospital were older, had longer lengths of stayed and consumed more resources, particularly in the ICU. In terms of potential funding discrepancies, our results showed inter-hospital patients with minor injuries had the largest discrepancies compared to patients transported pre-hospital. Currently, hospitals in NSW receive variable amounts of pre-hospital and inter-hospital HEMS transports. Given the differences between HEMS patients transported directly from the scene and inter-hospital, future funding models also need to account for these differences.